← Patent-cliff monitor Loss of exclusivity January 2038 latest FDA-listed patent expiry
Drug detail Brand name ORSERDU Active ingredient ELACESTRANT HYDROCHLORIDE Strength EQ 86MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval January 2023 Marketing status RX
Listed patents Patent Expires Type 10745343 January 2038 use U-3523 10385008 January 2038 substance, product 11819480 February 2037 use U-3523 10420734 October 2036 use U-3524 10071066 October 2034 use U-3524 11779552 October 2034 use U-3524 7612114 August 2026 substance, product
Regulatory exclusivity Code Expires NCE January 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.